In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute found.
The United States is projected to lose its measles elimination status, marking a troubling reversal after more than two decades in which the virus was no longer considered endemic.
